1. GPCR Inhibition in Treating Lymphoma
- Author
-
Marilia Barreca, Virginia Spanò, Maria V. Raimondi, Roberta Bivacqua, Stefano Giuffrida, Alessandra Montalbano, Andrea Cavalli, Francesco Bertoni, Paola Barraja, Barreca M., Spano' V., Raimondi M.V., Bivacqua R., Giuffrida S., Montalbano A., Cavalli A., Bertoni F., and Barraja P.
- Subjects
CXCR4 ,G protein-coupled receptors ,DLBCL ,Organic Chemistry ,Drug Discovery ,lymphoma ,MCL ,Biochemistry ,GPCRs - Abstract
G protein-coupled receptors (GPCRs) are important classes of cell surface receptors involved in multiple physiological functions. Aberrant expression, upregulation, and mutation of GPCR signaling pathways are frequent in many types of cancers, promoting hyperproliferation, angiogenesis, and metastasis. Recent studies showed that alterations of GPCRs are involved in different lymphoma types. Herein, we review the synthetic strategies to obtain GPCR inhibitors, focusing on CXCR4 inhibitors which represent most of the GPCR inhibitors available in the market or under preclinical investigations for these diseases.
- Published
- 2022